Robert Azelby Insider Trading $JUNO Juno Therapeutics, Inc.

FREE EMAIL WATCHDOG

Get free email notifications about insider trading for Robert Azelby.

  • Your email is safe with us.
  • The service is free and you can unsubscribe at any time.

General | Insider Transactions | Monthly Overview

Get the latest insider transactions of Robert Azelby. Robert Azelby is Director in IMMUNOMEDICS INC ($IMMU) and Director in Cascadian Therapeutics, Inc. ($CASC) and President and CEO in ALDER BIOPHARMACEUTICALS INC ($ALDR) and Director in Clovis Oncology, Inc. ($CLVS) and EVP & Chief Commercial Officer in Juno Therapeutics, Inc. ($JUNO) and See Remarks in Juno Therapeutics, Inc. ($JUNO).

Robert Azelby in Juno Therapeutics, Inc.

Trading Symbol: JUNO
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Robert Azelby: EVP & Chief Commercial Officer, See Remarks
Holdings: 82,112 shares
Current Value: $1,704,645
Latest Transaction: Mar 07 2018
$JUNO Market Capitalization: $2.09B
$JUNO Previous Close: $20.76

Last 4 weeks trend: HOLD
Last 3 months trend: HOLD

Latest Insider Trading Transactions of Robert Azelby in Juno Therapeutics, Inc.

1 Week2 Weeks1 Month3 Months6 Months1 Year2 Years
No. of Purchases0000000
Value of Purchases ($)0000000
No. of Sales0000000
Value of Sales ($)0000000

Sentiment: All, ALDR, CASC, CLVS, IMMU, JUNO

Page:   1

DateTickerCompanyOwnerRelationship Transaction Code Cost ($) Shares Transaction Value ($) Total Shares % Holdings
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseD20.7698,5452,045,7940
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseD25.2930,002758,7510
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseD51.7693,2944,828,8970
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellD0.0035,8930035.9 K to 0 (-100.00 %)
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellD0.0025,639035,89361.5 K to 35.9 K (-41.67 %)
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellD0.0020,580061,53282.1 K to 61.5 K (-25.06 %)
Mar 07 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellD0.007,500082,11289.6 K to 82.1 K (-8.37 %)
Feb 14 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS85.554,157355,63189,61493.8 K to 89.6 K (-4.43 %)
Feb 09 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM20.762,66355,28498,545
Feb 09 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM25.2983421,09230,002
Feb 09 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS85.773,497299,93893,77197.3 K to 93.8 K (-3.60 %)
Feb 09 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM20.762,66355,28497,26894.6 K to 97.3 K (+2.81 %)
Feb 09 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM25.2983421,09294,60593.8 K to 94.6 K (+0.89 %)
Feb 09 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Payment of ExerciseF85.492,700230,82393,77196.5 K to 93.8 K (-2.80 %)
Feb 02 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM51.764,167215,68493,294
Feb 02 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS85.784,167357,44596,471100.6 K to 96.5 K (-4.14 %)
Feb 02 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM51.764,167215,684100,63896.5 K to 100.6 K (+4.32 %)
Feb 02 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...GrantA0.0025,639096,47170.8 K to 96.5 K (+36.20 %)
Jan 24 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM51.76102,5395,307,41997,461
Jan 24 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS86.25102,5398,843,98970,832173.4 K to 70.8 K (-59.14 %)
Jan 24 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM51.76102,5395,307,419173,37170.8 K to 173.4 K (+144.76 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM20.7626,633552,901101,208
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM25.292,49863,17430,836
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS69.957,990558,90170,83278.8 K to 70.8 K (-10.14 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS68.1021,1411,439,70278,822100 K to 78.8 K (-21.15 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM20.7626,633552,90199,96373.3 K to 100 K (+36.32 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM25.292,49863,17473,33070.8 K to 73.3 K (+3.53 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM20.7626,633552,901101,208
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM25.292,49863,17430,836
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS69.957,990558,90170,83278.8 K to 70.8 K (-10.14 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS68.1021,1411,439,70278,822100 K to 78.8 K (-21.15 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM20.7626,633552,90199,96373.3 K to 100 K (+36.32 %)
Jan 19 2018JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM25.292,49863,17473,33070.8 K to 73.3 K (+3.53 %)
Dec 20 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS44.961,81681,64770,83272.6 K to 70.8 K (-2.50 %)
Nov 09 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Payment of ExerciseF55.9868438,29072,64873.3 K to 72.6 K (-0.93 %)
Nov 03 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseM25.296,666168,58333,334
Nov 03 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS54.956,666366,29773,33280 K to 73.3 K (-8.33 %)
Nov 03 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...BuyM25.296,666168,58379,99873.3 K to 80 K (+9.09 %)
Oct 20 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...GrantA0.0035,893073,33237.4 K to 73.3 K (+95.87 %)
Sep 14 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS44.9512,850577,60837,43950.3 K to 37.4 K (-25.55 %)
Aug 31 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS39.9512,869514,11750,28963.2 K to 50.3 K (-20.38 %)
Feb 09 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseA20.76127,8412,653,979127,841
Feb 09 2017JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...GrantA0.0027,439063,15835.7 K to 63.2 K (+76.82 %)
Nov 10 2016JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...Option ExerciseA25.2940,0001,011,60040,000
Nov 10 2016JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...SellS24.1412,921311,84835,71948.6 K to 35.7 K (-26.56 %)
Nov 10 2016JUNOJuno Therapeutics, ...Azelby RobertEVP & Chief Commerc ...GrantA0.0010,000048,64038.6 K to 48.6 K (+25.88 %)
Nov 02 2015JUNOJuno Therapeutics, ...Azelby RobertSee RemarksOption ExerciseA51.76200,00010,352,000200,000
Nov 02 2015JUNOJuno Therapeutics, ...Azelby RobertSee RemarksGrantA0.0038,640038,6400 to 38.6 K

Page:   1

Contact us | Follow us on Twitter